0000000000033830

AUTHOR

Ingo Vernaleken

showing 25 related works from this author

Equilibrium in [18F]fallypride PET

2010

18F-fallyprideNeurologyChemistryCognitive NeuroscienceRadiochemistryNeuroImage
researchProduct

Relationship between prefrontal cognitive functions and dopaminergic transmission: A [18F]-fluoro-l-DOPA PET study

2006

NeurologyTransmission (telecommunications)ChemistryCognitive NeuroscienceDopaminergicCognitionNeuroscienceNeuroImage
researchProduct

A comparative analysis of striatal and extrastriatal D2/D3 binding of five pharmacologically different “atypical” antipsychotics

2006

Neurologybusiness.industryCognitive NeuroscienceMedicinePharmacologybusinessNeuroImage
researchProduct

The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia.

2005

Positron emission tomography (PET) studies reveal that clozapine at clinically used doses occupies less than 60% of D2/D3 dopamine receptors in human striatum. Here, the occupancy of D2/D3 dopamine receptors by clozapine in patients with schizophrenia was determined to test the hypothesis that clozapine binds preferentially to extrastriatal dopamine receptors. A total of 15 clozapine-treated inpatients with schizophrenia underwent a [18F]fallypride PET scan. Receptor occupancy was calculated as percent reduction in binding potential relative to unblocked values measured in seven normal volunteers. Mean D2/D3 receptor occupancy was statistically significantly higher in cortical (inferior tem…

AdultMalemedicine.medical_specialtyPsychosisPyrrolidinesDopamineStriatumBinding CompetitiveReceptors DopamineDopamine receptor D3Internal medicinemedicineHumansClozapineClozapinePharmacologyTemporal cortexDose-Response Relationship DrugChemistryReceptors Dopamine D2PutamenReceptors Dopamine D3Middle Agedmedicine.diseaseCorpus StriatumTemporal LobePsychiatry and Mental healthEndocrinologyFallyprideDopamine receptorAnesthesiaPositron-Emission TomographyBenzamidesSchizophreniaFemalemedicine.drugAntipsychotic AgentsNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
researchProduct

Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas

2010

Quetiapine is next to clozapine an antipsychotic agent that exerts hardly any extrapyramidal side-effects at clinical efficacious doses. Some previous receptor occupancy studies reported preferential extrastriatal D2/3 receptor (D2/3R)-binding properties of second-generation antipsychotics and suggested this as possible reason for improved tolerability. This positron emission tomography (PET) investigation was designed to compare the occupancy of dopamine D2/3Rs by quetiapine in striatal and extrastriatal brain regions. Therefore, a cohort of 16 quetiapine-treated psychotic patients underwent an [18F]fallypride (FP) PET scan. Due to the high affinity of FP and its comparatively long half-li…

AdultMaleDibenzothiazepinesPyrrolidinesCaudate nucleusPharmacologyBinding CompetitiveQuetiapine FumarateYoung AdultQuetiapine FumarateDopamine receptor D2HumansMedicinePharmacology (medical)ClozapineVisual CortexPharmacologyTemporal cortexReceptors Dopamine D2business.industryReceptors Dopamine D3Binding potentialMiddle AgedCorpus StriatumTemporal LobePsychiatry and Mental healthFallypridePositron-Emission TomographyBenzamidesSchizophreniaQuetiapineFemalebusinessAntipsychotic Agentsmedicine.drugThe International Journal of Neuropsychopharmacology
researchProduct

Alcohol Consumption in HealthyOPRM1G Allele Carriers and Its Association with Impulsive Behavior

2015

AIMS: A link between alcohol use disorders (AUD) and impulsivity is well established. As there is evidence for the heritability of AUD, the investigation of the underlying genetic disposition for both conditions is an important issue. An association between AUD and a coding single nucleotide polymorphism (SNP) (rs1799971 encoding an Asn40Asp amino acid substitution, A118G) within the µ-opioid receptor 1 gene (OPRM1) has been reported. Therefore we tested the association between the OPRM1 A118G polymorphism and drinking as well as impulsive behavior in social drinkers. METHODS: A total of 214 healthy male social drinkers were recruited. Each participant was genotyped for the OPRM1 A118G vari…

AdultMalemedicine.medical_specialtyAlcohol DrinkingGenotypePerseverationReceptors Opioid muPoison controlSingle-nucleotide polymorphismImpulsivityPolymorphism Single NucleotideYoung AdultPolymorphism (computer science)medicineGenetic predispositionHumansGenetic Predisposition to DiseaseAllelePsychiatryAllelesAlcohol Use Disorders Identification TestGeneral MedicineMiddle AgedImpulsive Behaviormedicine.symptomPsychologyClinical psychologyAlcohol and Alcoholism
researchProduct

Opiate-induced dopamine release is modulated by severity of alcohol dependence: an [(18)F]fallypride positron emission tomography study.

2011

Background Preclinical data implicate the reinforcing effects of alcohol to be mediated by interaction between the opioid and dopamine systems of the brain. Specifically, alcohol-induced release of β-endorphins stimulates μ-opioid receptors (MORs), which is believed to cause dopamine release in the brain reward system. Individual differences in opioid or dopamine neurotransmission have been suggested to be responsible for enhanced liability to abuse alcohol. In the present study, a single dose of the MOR agonist remifentanil was administered in detoxified alcohol-dependent patients and healthy control subjects to mimic the β-endorphin-releasing properties of ethanol and to assess the effect…

AgonistAdultMaleFluorine RadioisotopesPyrrolidinesmedicine.drug_classDopamineReceptors Opioid muPharmacologySeverity of Illness IndexRemifentanilRadioligand AssayDopamine receptor D1PiperidinesDopamine receptor D3DopaminemedicineLimbic SystemHumansBiological PsychiatryReceptors Dopamine D2PutamenFunctional NeuroimagingVentral striatumAlcohol dependenceMiddle AgedAnalgesics OpioidBehavior AddictiveAlcoholismmedicine.anatomical_structurenervous systemFallypridePositron-Emission TomographyBenzamidesPsychologymedicine.drugBiological psychiatry
researchProduct

PET Studies of Net Blood—Brain Clearance of FDOPA to Human Brain: Age-Dependent Decline of [18F]Fluorodopamine Storage Capacity

2005

Conventional methods for the graphical analysis of 6-[18F]fluorodopa (FDOPA)/positron emission tomography (PET) recordings ( Kappin) may be prone to negative bias because of oversubtraction of the precursor pool in the region of interest, and because of diffusion of decarboxylated FDOPA metabolites from the brain. These effects may reduce the sensitivity of FDOPA/PET for the detection of age-related changes in dopamine innervations. To test for these biasing effects, we have used a constrained compartmental analysis to calculate the brain concentrations of the plasma metabolite 3- O-methyl-FDOPA (OMFD) during 120 mins of FDOPA circulation in healthy young, healthy elderly, and Parkinson's …

AdultAgingFluorine Radioisotopesmedicine.medical_specialtyMetaboliteDiffusionCentral nervous system diseasechemistry.chemical_compoundDopamineInternal medicinemedicineHumans18F-fluorodopamineFluorodopamedicine.diagnostic_testbusiness.industryPutamenBrainHuman brainMiddle Agedmedicine.diseaseDihydroxyphenylalanineEndocrinologymedicine.anatomical_structureNeurologychemistryPositron emission tomographyPositron-Emission TomographyNeurology (clinical)Cardiology and Cardiovascular MedicineNuclear medicinebusinessmedicine.drugJournal of Cerebral Blood Flow & Metabolism
researchProduct

Elevated [18F]FDOPA utilization in the periaqueductal gray and medial nucleus accumbens of patients with early Parkinson's disease

2010

Udgivelsesdato: 2010-Feb-15 PET studies with the DOPA decarboxylase substrate 6-[(18)F]fluoro-l-DOPA (FDOPA) reveal the storage of [(18)F]-fluorodopamine within synaptic vesicles, mainly of dopamine fibres. As such, FDOPA PET is a sensitive indicator of the integrity of the nigrostriatal dopamine innervation. Nonetheless, there have been several reports of focal elevations of FDOPA utilization in brain of patients with Parkinson's disease (PD), all based on reference tissue methods. To investigate this phenomenon further, we used voxel-wise steady-state kinetic analysis to search for regions of elevated FDOPA utilization (K; ml g(-1) min(-1)) and steady-state trapping (V(d); ml g(-1)) in a …

AdultMalemedicine.medical_specialtyParkinson's diseaseMetabolic Clearance RateCognitive NeuroscienceStriatumNucleus accumbensPeriaqueductal grayNucleus AccumbensDopamineInternal medicinemedicineHumansPeriaqueductal GrayAgedAromatic L-amino acid decarboxylasebusiness.industryParkinsonismPutamenParkinson DiseaseMiddle Agedmedicine.diseaseDihydroxyphenylalanineEndocrinologyNeurologyPositron-Emission TomographyFemaleRadiopharmaceuticalsbusinessNeurosciencemedicine.drugNeuroImage
researchProduct

Acute effect of intravenously applied alcohol in the human striatal and extrastriatal D2 /D3 dopamine system

2016

Investigations on the acute effects of alcohol in the human mesolimbic dopamine D2 /D3 receptor system have yielded conflicting results. With respect to the effects of alcohol on extrastriatal D2 /D3 dopamine receptors no investigations have been reported yet. Therefore we applied PET imaging using the postsynaptic dopamine D2 /D3 receptor ligand [18 F]fallypride addressing the question, whether intravenously applied alcohol stimulates the extrastriatal and striatal dopamine system. We measured subjective effects of alcohol and made correlation analyses with the striatal and extrastriatal D2 /D3 binding potential. Twenty-four healthy male μ-opioid receptor (OPRM1)118G allele carriers underw…

0301 basic medicinePharmacologymedicine.medical_specialtyMedicine (miscellaneous)D3 dopamine receptor binding03 medical and health sciencesPsychiatry and Mental health030104 developmental biology0302 clinical medicineEndocrinologyFallyprideDopamine receptorDopamine receptor D3DopamineInternal medicineDopamine receptor D2medicineOrbitofrontal cortexPsychologyPrefrontal cortexNeuroscience030217 neurology & neurosurgerymedicine.drugAddiction Biology
researchProduct

Vulnerability to psychotogenic effects of ketamine is associated with elevated D2/3-receptor availability.

2012

Previous positron emission tomography (PET) studies employing competition paradigms have shown either no change or substantial declines in striatal ( 11 C)-raclopride binding after challenge with psychotogenic doses of the N-methyl-D-aspartate antagonist ketamine. We sought to probe the relationship between the severity of ketamine-induced psychotic symptoms and altered dopamine D2/3 receptor availability throughout brain using the high affinity ligand ( 18 F)-fallypride (FP). PET recordings were obtained in a group of 10 healthy, young male volunteers, in a placebo condition, and in the course of an infusion with ketamine at a psychotomimetic dose. Administration of the Positive and Negati…

AdultMalemedicine.medical_specialtyPsychosisCaudate nucleusContext (language use)Genetics BehavioralYoung AdultInternal medicinemedicineHumansPharmacology (medical)Single-Blind MethodPharmacologyRaclopridePositive and Negative Syndrome ScaleReceptors Dopamine D2Receptors Dopamine D3Psychotomimeticmedicine.diseaseUp-RegulationPsychiatry and Mental healthEndocrinologyFallyprideSchizophreniaAnesthesiaPositron-Emission TomographyBenzamidesKetaminePsychologymedicine.drugProtein BindingThe international journal of neuropsychopharmacology
researchProduct

Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclo…

2008

To elucidate the Batypicality( of ziprasidone, its striatal and extrastriatal D2/D3-receptor binding was characterized in patients with schizophrenia under steady-state conditions. These data were compared with striatal receptor occupancy values after single-dose ziprasidone ingestion in healthy controls. ( 18 F)fallypride positron emission tomography (PET) recordings were obtained in 15 patients under steady-state ziprasidone treatment at varying time points after the last dose. Binding potentials were calculated for striatal and extrastriatal regions. D2/D3-receptor occupancies were expressed relative to binding potentials in 8 unmedicated patients. In a parallel ( 11 C)raclopride-PET stu…

AdultMalemedicine.medical_specialtyFluorine RadioisotopesPyrrolidinesTime Factorsmedicine.drug_classAtypical antipsychoticPharmacologyBinding CompetitiveBasal GangliaPiperazinesYoung AdultDopamine receptor D3Internal medicinemedicineHaloperidolHumansPharmacology (medical)ZiprasidoneCarbon RadioisotopesTemporal cortexRacloprideDose-Response Relationship DrugChemistryReceptors Dopamine D2Dopamine antagonistReceptors Dopamine D3Psychiatry and Mental healthThiazolesEndocrinologyFallyprideRaclopridePositron-Emission TomographyBenzamidesSchizophreniaDopamine AntagonistsFemaleRadiopharmaceuticalsmedicine.drugAntipsychotic AgentsJournal of clinical psychopharmacology
researchProduct

The applicability of SRTM in [18F]fallypride PET investigations: Impact of scan durations

2011

The high-affinity radioligand [18F]fallypride (FP) is frequently used for quantification of striatal/extrastriatal D2/3 receptors and the receptor occupancies of antipsychotics (APs). Its 110 minutes half-life allows long scan durations. However, the optimum scan duration is a matter of debate. This investigation focuses on scan-duration-related effects on simplified reference tissue model (SRTM) results and the time point of transient equilibrium in a large sample of dynamic FP positron emission tomography (PET) scans. Fifty drug-free and 50 AP-treated subjects underwent FP-PET scans (180 minutes scan duration). The binding potential ( BPND) of the putamen, thalamus, and temporal cortex w…

AdultMalePyrrolidinesTime FactorsMaterials scienceAdolescentShuttle Radar Topography MissionRadioligand AssayYoung AdultRadioligandmedicineHumansTemporal cortexTransient equilibriummedicine.diagnostic_testReceptors Dopamine D2business.industryMental DisordersPutamenReceptors Dopamine D3Binding potentialMiddle AgedCorpus StriatumNeurologyFallypridePositron emission tomographyPositron-Emission TomographyBenzamidesFemaleOriginal ArticleNeurology (clinical)Cardiology and Cardiovascular MedicineNuclear medicinebusinessAntipsychotic AgentsJournal of Cerebral Blood Flow & Metabolism
researchProduct

[ 18 F]Fluoroethylflumazenil: a novel tracer for PET imaging of human benzodiazepine receptors

2001

5-(2'-[18F]Fluoroethyl)flumazenil ([18F]FEF) is a fluorine-18 labelled positron emission tomography (PET) tracer for central benzodiazepine receptors. Compared with the established [11C]flumazenil, it has the advantage of the longer half-life of the fluorine-18 label. After optimisation of its synthesis and determination of its in vitro receptor affinities, we performed first PET studies in humans. PET studies in seven healthy human volunteers were performed on a Siemens ECAT EXACT whole-body scanner after injection of 100-280 MBq [L8F]FEF. In two subjects, a second PET scan was conducted after pretreatment with unlabelled flumazenil (1 mg or 2.5 mg i.v., 3 min before tracer injection). A t…

FlumazenilMalemedicine.drug_classNuclear magnetic resonancemedicineHumansRadiology Nuclear Medicine and imagingReceptorTemporal cortexBenzodiazepineChemistrybusiness.industryGABAA receptorBrainHalf-lifeBinding potentialGeneral MedicineHuman brainReceptors GABA-Amedicine.anatomical_structureFlumazenilRadiopharmaceuticalsNuclear medicinebusinessTomography Emission-Computedmedicine.drugEuropean Journal of Nuclear Medicine and Molecular Imaging
researchProduct

Asymmetry in dopamine D2/3 receptors of caudate nucleus is lost with age

2007

Molecular and functional imaging techniques reveal evidence for lateralization of human cerebral function. Based on animal data, we hypothesized that asymmetry in dopamine neurotransmission declines during normal aging. In order to test this hypothesis, we measured dopamine D2/3 receptor availability with [18F]desmethoxyfallypride-PET (DMFP) in putamen and caudate nucleus (NC) of 21 healthy, right-handed males (24-60 years; 35+/-10). For volumetric analysis, high-resolution T1-weighted MR-images were obtained in 18 of the PET-subjects in order to assess possible age-related decreases in NC and putamen volume. The calculated DMFP binding potentials (BP) showed a right-ward asymmetry in NC of…

AdultMaleAgingmedicine.medical_specialtyCognitive NeuroscienceCaudate nucleusNeurotransmissionFunctional LateralityLateralization of brain functionAnimal dataDopamineDopamine receptor D2Internal medicineSalicylamidesmedicineHumansTissue DistributionReceptors Dopamine D2PutamenReceptors Dopamine D3Middle AgedEndocrinologyNeurologyDopamine receptorPositron-Emission TomographyCaudate NucleusRadiopharmaceuticalsPsychologyNeurosciencemedicine.drugNeuroImage
researchProduct

Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge.

2006

In animal studies, acute antipsychotic treatment was shown to enhance striatal DOPA-decarboxylase (DDC) activity. However, this phenomenon has not been demonstrated in humans by positron emission tomography (PET). Therefore, we investigated acute haloperidol effects on DDC activity in humans using [18F]fluorodopa (FDOPA) PET. Nine healthy volunteers were scanned with FDOPA in drug-free baseline conditions and after 3 days of haloperidol treatment (5 mg/day). A continuous performance test (CPT) was administered in both conditions. The net blood-brain clearance of FDOPA (K(in)app) in striatum, mesencephalon, and medial prefrontal cortex was calculated by volume-of-interest analysis. The macro…

AdultMalemedicine.medical_specialtyFluorine RadioisotopesCognitive NeurosciencePrefrontal CortexStimulationStriatumNeuropsychological TestsMesencephalonInternal medicineBasal gangliamedicineHaloperidolImage Processing Computer-AssistedHumansAttentionFluorodopaPrefrontal cortexDominance Cerebralmedicine.diagnostic_testbusiness.industryPutamenBrainMiddle AgedCorpus StriatumDihydroxyphenylalanineEndocrinologyNeurologyPattern Recognition VisualPositron emission tomographyBlood-Brain BarrierPositron-Emission TomographyHaloperidolNuclear medicinebusinessPsychomotor Performancemedicine.drugNeuroImage
researchProduct

Therapeutic monitoring of new antipsychotic drugs.

2004

Typical antipsychotic drugs qualify for therapeutic drug monitoring (TDM) primarily for the following reasons: control of compliance and avoidance of extrapyramidal side effects by keeping chronic exposure to minimal effective blood levels. For the atypical antipsychotic clozapine, drug safety is another reason to use TDM. With regard to the new antipsychotics risperidone, olanzapine, quetiapine, amisulpride, ziprasidone, and aripiprazole, which have been introduced in the clinic during the last few years, the rationale to use TDM is a matter of debate. Positron emission tomography (PET), which enables measurement of the occupancy of dopamine D2 receptors, revealed that receptor occupancy c…

PharmacologyOlanzapinemedicine.diagnostic_testDose-Response Relationship Drugmedicine.drug_classbusiness.industryReceptors Dopamine D2medicine.medical_treatmentAtypical antipsychoticPharmacologyTypical antipsychoticStructure-Activity RelationshipTherapeutic drug monitoringmedicineQuetiapineHumansPharmacology (medical)ZiprasidoneAmisulprideDrug MonitoringAntipsychoticbusinessmedicine.drugAntipsychotic AgentsTherapeutic drug monitoring
researchProduct

High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia.

2003

The 'atypicality' of the antipsychotic drug, amisulpride, has been attributed to preferential extrastriatal binding. Previous investigations of striatal D2 receptor occupancy by amisulpride revealed conflicting results. The aim of this PET study was to measure the striatal occupancy by amisulpride and to correlate it with the corresponding drug plasma concentrations. Nine amisulpride-treated patients and 12 healthy volunteers serving as controls were studied with PET and [18F]desmethoxyfallypride. Occupancy values and plasma concentrations were nonlinearly fitted to an E max model. Results showed 43-85% (putamen) and 67-90% (caudate) D2-like receptor occupancy. Plasma amisulpride concentrat…

AdultMaleOccupancyPharmacologyDopamine receptor D2Image Interpretation Computer-AssistedSalicylamidesmedicineHumansPharmacology (medical)AmisulprideReceptorPharmacologyCerebral CortexChemistryReceptors Dopamine D2PutamenDesmethoxyfallypridePutamenMiddle Agedmedicine.diseaseNeostriatumPsychiatry and Mental healthSchizophreniaDopamine receptorArea Under CurvePositron-Emission TomographySchizophreniaFemaleAmisulprideCaudate NucleusRadiopharmaceuticalsSulpirideAlgorithmsmedicine.drugAntipsychotic AgentsThe international journal of neuropsychopharmacology
researchProduct

Dopamine D2/D3 receptor availability and venturesomeness.

2011

The construct of impulsivity is considered as a major trait of personality. There is growing evidence that the mesolimbic dopamine system plays an important role in the modulation of impulsivity and venturesomeness, the two key components within the impulsivity-construct. The aim of the present study was to explore an association between trait impulsivity measured with self-assessment and the dopaminergic neurotransmission as measured by positron emission tomography (PET) in a cohort of healthy male subjects. In vivo D2/D3 receptor availability was determined with [(18)F]fallypride PET in 18 non-smoking healthy subjects. The character trait impulsivity was measured using the Impulsiveness-V…

AdultMaleSelf-AssessmentPyrrolidinesStatistics as TopicNeuroscience (miscellaneous)Neuropsychological TestsImpulsivityStatistical parametric mappingPersonality AssessmentBrain mappingDevelopmental psychologyCohort StudiesYoung AdultRisk-TakingDopamine receptor D3Dopamine receptor D2Surveys and QuestionnairesmedicineHumansRadiology Nuclear Medicine and imagingTemporal cortexBrain MappingReceptors Dopamine D2BrainPsychiatry and Mental healthFallypridePositron-Emission TomographyBenzamidesImpulsive Behaviormedicine.symptomPersonality Assessment InventoryPsychologyNeurosciencePsychiatry research
researchProduct

Baseline [18F]-FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: A positron emission tomog…

2007

The telencephalic dopamine innervations contribute to the modulation of cognitive processing. However, the relationship between cognitive effects of D(2/3)-receptor antagonism and dopamine transmission is not described in healthy subjects. We therefore tested effects of acute haloperidol (5 mg/d over 3 days) on continuous performance task (CPT) performance and 6-[(18)F]-fluoro-l-DOPA (FDOPA) PET parameters. Nine physically and mentally healthy male men performed two FDOPA-PET scans including arterial plasma withdrawal. Over 3 days before the second scan, all subjects were treated with 5 mg/d haloperidol orally. Using our novel steady-state analysis, we calculated the intrinsic rate of the c…

AdultMalemedicine.medical_specialtyCognitive NeuroscienceDopamineKineticsStriatumNeuropsychological TestsCognitionDopamineContinuous performance taskFluorodeoxyglucose F18Predictive Value of TestsInternal medicinemedicineHaloperidolImage Processing Computer-AssistedHumansEffects of sleep deprivation on cognitive performancePsychiatryBrain Chemistrymedicine.diagnostic_testHealthy subjectsReceptors Dopamine D3BrainMiddle AgedDopamine D2 Receptor AntagonistsEndocrinologyNeurologyPositron emission tomographyData Interpretation StatisticalPositron-Emission TomographyDopamine AntagonistsHaloperidolFemaleRadiopharmaceuticalsPsychologyAlgorithmsPsychomotor Performancemedicine.drugNeuroImage
researchProduct

Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo

2003

Udgivelsesdato: 2003-Apr The antipsychotic effect of neuroleptics cannot be attributed entirely to acute blockade of postsynaptic D(2)-like dopamine (DA) receptors, but may arise in conjunction with the delayed depolarization block of the presynaptic neurons and reduced DA synthesis capacity. Whereas the phenomenon of depolarization block is well established in animals, it is unknown if a similar phenomenon occurs in humans treated with neuroleptics. We hypothesized that haloperidol treatment should result in decreased DA synthesis capacity. We used 6-[(18)F]fluoro-L-dopa (FDOPA) and positron emission tomography (PET) in conjunction with compartmental modeling to measure the relative activi…

AdultMalePsychosismedicine.medical_specialtyPatientsDopamineDown-RegulationStatistics NonparametricDopamineInternal medicinemedicineHaloperidolHumansPharmacologybusiness.industryPutamenDopamine antagonistBrainDepolarizationHuman brainMiddle Agedmedicine.diseasePsychiatry and Mental healthEndocrinologymedicine.anatomical_structureCerebral cortexAnesthesiaSchizophreniaHaloperidolbusinessTomography Emission-Computedmedicine.drug
researchProduct

Age-dependent decline of steady state dopamine storage capacity of human brain: an FDOPA PET study.

2010

Conventional indices of the utilization of FDOPA in living human brain have not consistently revealed important declines in dopamine function with normal aging. However, most methods of kinetic analysis have assumed irreversible trapping of decarboxylated FDOPA metabolites in brain, an assumption that is violated even in PET recordings of short duration. Therefore, we have developed methods for the calculation of steady-state storage of FDOPA together with its decarboxylated metabolites (V(d), mlg(-1)), based upon improved kinetic analysis of 120-min emission recordings. In a group of 28 normal male subjects, of age ranging from 23 to 73 years, the magnitude of V(d) in the striatum and in e…

AdultMalemedicine.medical_specialtyAgingMonoamine oxidaseDopamineModels NeurologicalStriatumchemistry.chemical_compoundYoung AdultDopamineInternal medicinemedicineHumansNeurotransmitterAgedCerebral CortexAromatic L-amino acid decarboxylaseChemistryGeneral NeuroscienceBrainHuman brainMiddle AgedCorpus StriatumKineticsmedicine.anatomical_structureEndocrinologyCerebral cortexPositron-Emission TomographyCatecholamineDopa DecarboxylaseNeurology (clinical)Geriatrics and GerontologyDevelopmental Biologymedicine.drugNeurobiology of aging
researchProduct

'Prefrontal' cognitive performance of healthy subjects positively correlates with cerebral FDOPA influx: an exploratory [18F]-fluoro-L-DOPA-PET inves…

2006

Dopamine neurotransmission influences those cognitive processes, which are generally regarded as prefrontal cortical functions. In previous positron‐emission‐tomography (PET) studies, net blood‐brain clearance of [(18)F]‐fluoro‐l‐DOPA (FDOPA) correlated with impaired cognitive performance in patients with Parkinson's disease or schizophrenia. We hypothesized that FDOPA influx also correlates with performance of cognitive tasks associated with prefrontal functioning in healthy volunteers. The net blood‐brain clearance of FDOPA (K [Formula: see text]) was mapped in a group of 11 healthy volunteers and calculated in striatal volumes‐of‐interest. The Wisconsin‐Card‐Sorting‐Test (WCST), Stroop‐T…

AdultMaleElementary cognitive taskMetabolic Clearance RateDopamineCaudate nucleusPrefrontal CortexStriatumNeuropsychological Testsbehavioral disciplines and activitiesSynaptic TransmissionBasal GangliaFunctional LateralityCognitionMesencephalonReference ValuesBasal gangliaNeural PathwaysReaction TimeHumansRadiology Nuclear Medicine and imagingPrefrontal cortexResearch ArticlesBrain MappingRadiological and Ultrasound TechnologyReceptors Dopamine D2PutamenCognitive flexibilityPutamenMiddle AgedDihydroxyphenylalanineNeurologyBlood-Brain BarrierPositron-Emission TomographyNeurology (clinical)AnatomyCaudate NucleusPsychologyNeuroscienceStroop effectHuman brain mapping
researchProduct

MAOA-VNTR polymorphism modulates context-dependent dopamine release and aggressive behavior in males

2016

A recent [F-18]FDOPA-PET study reports negative correlations between dopamine synthesis rates and aggressive behavior. Since dopamine is among the substrates for monoamine oxidase A (MAOA), this investigation examines whether functional allelic variants of the MAOA tandem repeat (VNTR) promotor polymorphism, which is known to modulate aggressive behavior, influences dopamine release and aggression in response to violent visual stimuli. We selected from a genetic prescreening sample, strictly case-matched groups of 2 x 12 healthy male subjects with VNTRs predictive of high (MAOA-High) and low (MAOA-Low) MAOA expression. Subjects underwent pairs of PET sessions (dopamine D-2/3 ligand [F-18]DM…

Male0301 basic medicinemedicine.medical_specialtyGenotypeCognitive NeuroscienceDopamineContext (language use)Polymorphism Single NucleotideDevelopmental psychologyYoung Adult03 medical and health sciences0302 clinical medicineDopaminePolymorphism (computer science)Dopamine receptor D2Internal medicineImage Processing Computer-AssistedmedicineHumansMAOAYoung adultMonoamine OxidasebiologyAggressionDopaminergicBrainDMFPAggression030104 developmental biologyEndocrinologyPETNeurologyPositron-Emission Tomographybiology.proteinmedicine.symptomMonoamine oxidase APsychology030217 neurology & neurosurgerymedicine.drug
researchProduct

Positron emission tomography in CNS drug discovery and drug monitoring.

2014

Molecular imaging methods such as positron emission tomography (PET) are increasingly involved in the development of new drugs. Using radioactive tracers as imaging probes, PET allows the determination of the pharmacokinetic and pharmacodynamic properties of a drug candidate, via recording target engagement, the pattern of distribution, and metabolism. Because of the noninvasive nature and quantitative end point obtainable by molecular imaging, it seems inherently suited for the examination of a pharmaceutical’s behavior in the brain. Molecular imaging, most especially PET, can therefore be a valuable tool in CNS drug research. In this Perspective, we present the basic principles of PET, th…

DrugCentral Nervous Systemmedia_common.quotation_subjectDopamineGlutamic AcidPharmacologyPermeabilityReceptors DopamineDrug DiscoverymedicineAnimalsHumansRadioactive Tracersmedia_commonEnd pointmedicine.diagnostic_testChemistryDrug discoveryDrug candidateTarget engagementBrainModels ChemicalPharmaceutical PreparationsPositron emission tomographyPositron-Emission TomographyReceptors SerotoninSchizophreniaMolecular MedicineMolecular imagingDrug MonitoringGlycolysisBiomedical engineeringCentral Nervous System AgentsJournal of medicinal chemistry
researchProduct